Frontiers in Public Health (Jul 2022)
Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma
Abstract
No abstracts available.Keywords